Sanofi Comes for Novartis’ Radiopharma Crown With ‘Clinically Meaningful’ Pancreatic Tumor Data

Sanofi’s Orano Med-partnered radioligand therapy AlphaMedix achieved all primary efficacy endpoints, which included a measure of overall response rate, in the mid-stage ALPHAMEDIX-02 study.